A Prospective, Multi-center Registry for Patients with Short Bowel Syndrome
Sponsor: |
Shire-NPS Pharmaceuticals, Inc |
Enrolling: |
Male and Female Patients |
IRB Number: |
AAAR6066 |
U.S. Govt. ID: |
NCT01990040 |
Contact: |
Shilpa Ravella, MD: 212-305-3839 / sr3236@cumc.columbia.edu |
This is a global prospective, observational, multi-center registry to evaluate the long-term safety profile for patients with short bowel syndrome (SBS) who are treated with teduglutide in a routine clinical setting. The registry will also evaluate the long-term clinical outcomes in patients with SBS. SBS patients treated and not treated with teduglutide will be enrolled.
This study is closed
Investigator
Shilpa Ravella, MD
Do you or your child have Short Bowel Syndrome (SBS)? |
Yes |
No |